|
|
|
 |
FDA Approval Activities for this Drug…
Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823/S3 01/05/01 05/09/03 Exelon (rivastigmine tartrate) Capsules, 1.5 mg, 3 mg, 4.5 mg, & 6 mg., Novartis NDA 20-823 4/21/00 8/16/01 4/24/00 10/11/01 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type Exelon (rivastigmine tartrate) Solution, 2 mg/mL, Novartis NDA 21-025 4/21/00 4/24/00 4/24/00 4/11/02 Exelon Indication: is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon (RIVASTIGMINE), Novartis Pharmaceuticals | Exelon (rivastigmine) capsules, Novartis Pharma, Labeling Revision | Exelon (rivastigmine) oral solution, Novartis Pharma, Labeling Revision | Rivastigmine Tartrate Capsule, Watson Labs, Tentative Approval | Rivastigmine Tartrate Oral Solution, Ranbaxy Labs, Tentative Approval | Rivastigmine Tartrate Capsules, Sun Pharma, Tentative Approval | Rivastigmine Tartrate Capsules, Dr. Reddy’s Labs, Tentative Approval | Exelon (rivastigmine) Capsules, Novartis Pharma, New or Modified Indication | Exelon (rivastigmine) Liquid, Novartis Pharma, New or Modified Indication | Rivastigmine Tartrate Capsules, Sun Pharma, Approval | Rivastigmine Tartrate Capsules, Dr. Reddy’s Labs, Approval | Rivastigmine Tartrate Capsules, Watson Labs, Approval | Exelon (rivastigmine) Transdermal System, Novartis Pharmaceuticals Corp., Labeling Revision | Rivastigmine Tartrate Capsules, Orchid Healthcare, Tentative Approval
  
|